Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea.
Nephrol Dial Transplant. 2023 Feb 13;38(2):499-506. doi: 10.1093/ndt/gfac144.
Although cardiovascular disease is known to be one of the leading causes of death after kidney transplantation (KT), evidence on the risk difference of de novo major adverse cardiovascular events (MACEs) in kidney transplant recipients (KTRs) compared with that in dialysis patients or the general population (GP) remains rare.
We identified KTRs using the nationwide health insurance database in South Korea and then 1:1 matched them with the dialysis and GP controls without a pre-existing MACE. The primary endpoint was defined as de novo MACEs consisting of myocardial infarction, coronary revascularization and ischemic stroke. The secondary endpoints were all-cause mortality and death-censored graft failure (DCGF) in KTRs.
We included 4156 individuals in each of the three groups and followed them up for 4.7 years. De novo MACEs occurred in 3.7, 21.7 and 2.5 individuals per 1000 person-years in the KTRs, dialysis controls and GP controls, respectively. KTRs showed a lower MACE risk {adjusted hazard ratio (aHR) 0.16 [95% confidence interval (CI) 0.12-0.20], P < .001} than dialysis controls, whereas a similar MACE risk to GP controls [aHR 0.81 (95% CI 0.52-1.27), P = .365]. In addition, KTRs showed a similar MACE risk compared with the GP group, regardless of age, sex and the presence of comorbidities, including hypertension, diabetes and dyslipidemia. Among KTRs, de novo MACEs were associated with an increased risk of all-cause mortality, but not with DCGF.
De novo MACEs in KTRs were much lower than that in dialysis patients and had a similar risk to the GP, but once it occurred it caused elevated mortality risk in KTRs.
尽管心血管疾病是肾移植(KT)后死亡的主要原因之一,但关于肾移植受者(KTR)与透析患者或普通人群(GP)相比新发主要不良心血管事件(MACE)风险差异的证据仍然很少。
我们使用韩国全国健康保险数据库确定了 KTR,并将他们与没有预先存在的 MACE 的透析和 GP 对照组进行了 1:1 匹配。主要终点定义为新发 MACE,包括心肌梗死、冠状动脉血运重建和缺血性卒中。次要终点是 KTR 的全因死亡率和死亡校正移植物失败(DCGF)。
我们在三个组中各纳入了 4156 人,并随访了 4.7 年。KTR、透析对照组和 GP 对照组中,新发 MACE 分别为每 1000 人年 3.7、21.7 和 2.5 例。KTR 的 MACE 风险较低[校正后的危险比(aHR)0.16(95%置信区间[CI]0.12-0.20),P<.001],而与 GP 对照组的 MACE 风险相似[aHR 0.81(95% CI 0.52-1.27),P=0.365]。此外,无论年龄、性别以及是否存在高血压、糖尿病和血脂异常等合并症,KTR 的 MACE 风险与 GP 组相似。在 KTR 中,新发 MACE 与全因死亡率的增加相关,但与 DCGF 无关。
KTR 中的新发 MACE 明显低于透析患者,与 GP 相比风险相似,但一旦发生,会增加 KTR 的死亡率风险。